The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Epitopes Involved in Antibody-Mediated Protection from Ebola Virus
Abstract
To determine the ability of antibodies to provide protection from Ebola viruses, monoclonal antibodies (mAbs) to the Ebola glycoprotein were generated and evaluated for efficacy. We identified several protective mAbs directed toward five unique epitopes on Ebola glycoprotein. One of the epitopes is conserved among all Ebola viruses that are known to be pathogenic for humans. Some protective mAbs were also effective therapeutically when administered to mice 2 days after exposure to lethal Ebola virus. The identification of protective mAbs has important implications for developing vaccines and therapies for Ebola virus.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sanchez, A., Trappier, S. G., Mahy, B. W., Peters, C. J., & Nichol, S. T. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.8.3602 · Cited by 552
Processing of the Ebola virus glycoprotein by the proprotein convertase furin
Volchkov, V. E., Feldmann, H., Volchkova, V. A., & Klenk, H.-D. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.10.5762 · Cited by 497
A Mouse Model for Evaluation of Prophylaxis and Therapy of Ebola Hemorrhagic Fever
Bray, M., Davis, K., Geisbert, T., Schmaljohn, C., & Huggins, J. (1998) · The Journal of Infectious Diseases · doi:10.1086/515386 · Cited by 492
Self-citationVOLCHKOV, V. E., BECKER, S., VOLCHKOVA, V. A., TERNOVOJ, V. A., KOTOV, A. N., NETESOV, S. V., & KLENK, H.-D. (1995) · Virology · doi:10.1006/viro.1995.0052 · Cited by 375
An Introduction to Ebola: The Virus and the Disease
Peters, C. J., & LeDuc, J. W. (1999) · The Journal of Infectious Diseases · doi:10.1086/514322 · Cited by 260
Biochemical Analysis of the Secreted and Virion Glycoproteins of Ebola Virus
Sanchez, A., Yang, Z.-Y., Xu, L., Nabel, G. J., Crews, T., & Peters, C. J. (1998) · Journal of Virology · doi:10.1128/jvi.72.8.6442-6447.1998 · Cited by 235
Immunization for Ebola virus infection
Xu, L., Sanchez, A., Yang, Z.-Y., Zaki, S. R., Nabel, E. G., Nichol, S. T., & Nabel, G. J. (1998) · Nature Medicine · doi:10.1038/nm0198-037 · Cited by 196
Manipulation Of T-Cell Responses With Monoclonal Antibodies
Waldmann, H. (1989) · Annual Review of Immunology · doi:10.1146/annurev.immunol.7.1.407 · Cited by 194
Sanchez, A., Ksiazek, T. G., Rollin, P. E., Miranda, M. E. G., Trappier, S. G., Khan, A. S., Peters, C. J., & Nichol, S. T. (1999) · The Journal of Infectious Diseases · doi:10.1086/514282 · Cited by 166
Preparation and Use of Hyperimmune Serum for Prophylaxis and Therapy of Ebola Virus Infections
Зубавичене, Н. М., Sergeyev, N. N., Чепурнов, А. А., & Sv, N. (1999) · The Journal of Infectious Diseases · doi:10.1086/514294 · Cited by 130
Cited by
Feldmann, H., & Geisbert, T. W. (2011) · The Lancet · doi:10.1016/s0140-6736(10)60667-8 · Cited by 1,374
Ebola virus entry requires the cholesterol transporter Niemann–Pick C1
Carette, J. E., Raaben, M., Wong, A. C., Herbert, A. S., Obernosterer, G., Mulherkar, N., Kuehne, A. I., Kranzusch, P. J., Griffin, A. M., Ruthel, G., et al. (2011) · Nature · doi:10.1038/nature10348 · Cited by 1,303
Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp
Qiu, X., Wong, G., Audet, J., Bello, A., Fernando, L., Alimonti, J. B., Fausther-Bovendo, H., Wei, H., Aviles, J., Hiatt, E., et al. (2014) · Nature · doi:10.1038/nature13777 · Cited by 987
Expanding roles for CD4+ T cells in immunity to viruses
Swain, S. L., McKinstry, K. K., & Strutt, T. M. (2012) · Nature Reviews Immunology · doi:10.1038/nri3152 · Cited by 956
Adenoviruses as vaccine vectors
Tatsis, N., & Ertl, H. C. J. (2004) · Molecular Therapy · doi:10.1016/j.ymthe.2004.07.013 · Cited by 669
Development of a preventive vaccine for Ebola virus infection in primates
Sullivan, N. J., Sanchez, A., Rollin, P. E., Yang, Z.-Y., & Nabel, G. J. (2000) · Nature · doi:10.1038/35046108 · Cited by 663
Dai, L., Song, J., Lu, X., Deng, Y.-Q., Musyoki, A. M., Cheng, H., Zhang, Y., Yuan, Y., Song, H., Haywood, J., et al. (2016) · Cell Host & Microbe · doi:10.1016/j.chom.2016.04.013 · Cited by 502
Bavari, S., Bosio, C. M., Wiegand, E., Ruthel, G., Will, A. B., Geisbert, T. W., Hevey, M., Schmaljohn, C., Schmaljohn, A., & Aman, M. J. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20011500 · Cited by 432
Self-citationChahal, J. S., Khan, O. F., Cooper, C. L., McPartlan, J. S., Tsosie, J. K., Tilley, L. D., Sidik, S. M., Lourido, S., Langer, R., Bavari, S., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1600299113 · Cited by 414
“Membranes were blocked with 10% milk in TBS-T and incubated with the following antibodies for detection in blocking buffer for 2–4 h at room temperature: for cOVA detection, rabbit polyclonal to OVA and HRP-conjugated, ab20415 (Abcam) diluted 1:3,000; for HA detection, single-chain alpaca nanobody VHH68 (70) diluted 1…”
MethodBard, F., Barbour, R., Cannon, C., Carretto, R., Fox, M., Games, D., Guido, T., Hoenow, K., Hu, K., Johnson-Wood, K., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0436286100 · Cited by 411
Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody
Corti, D., Misasi, J., Mulangu, S., Stanley, D. A., Kanekiyo, M., Wollen, S., Ploquin, A., Doria-Rose, N. A., Staupe, R. P., Bailey, M., et al. (2016) · Science · doi:10.1126/science.aad5224 · Cited by 408
Inflammatory responses in Ebola virus-infected patients
BAIZE, S., LEROY, E. M., GEORGES, A. J., GEORGES-COURBOT, M.-C., CAPRON, M., BEDJABAGA, I., LANSOUD-SOUKATE, J., & MAVOUNGOU, E. (2002) · Clinical and Experimental Immunology · doi:10.1046/j.1365-2249.2002.01800.x · Cited by 370
Olinger, G. G., Pettitt, J., Kim, D., Working, C., Bohorov, O., Bratcher, B., Hiatt, E., Hume, S. D., Johnson, A. K., Morton, J., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1213709109 · Cited by 366
FDA-Approved Selective Estrogen Receptor Modulators Inhibit Ebola Virus Infection
Johansen, L. M., Brannan, J. M., Delos, S. E., Shoemaker, C. J., Stossel, A., Lear, C., Hoffstrom, B. G., DeWald, L. E., Schornberg, K. L., Scully, C., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005471 · Cited by 332
Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibody
Nowakowski, A., Wang, C., Powers, D. B., Amersdorfer, P., Smith, T. J., Montgomery, V. A., Sheridan, R., Blake, R., Smith, L. A., & Marks, J. D. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.172229899 · Cited by 331
Huber, V. C., Lynch, J. M., Bucher, D. J., Le, J., & Metzger, D. W. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.12.7381 · Cited by 319
Antiviral antibody responses: the two extremes of a wide spectrum
Hangartner, L., Zinkernagel, R. M., & Hengartner, H. (2006) · Nature Reviews Immunology · doi:10.1038/nri1783 · Cited by 314
Huber, V. C., McKeon, R. M., Brackin, M. N., Miller, L. A., Keating, R., Brown, S. A., Makarova, N., Perez, D. R., MacDonald, G. H., & McCullers, J. A. (2006) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00156-06 · Cited by 311
Ebola virus: from discovery to vaccine
Feldmann, H., Jones, S., Klenk, H.-D., & Schnittler, H.-J. (2003) · Nature Reviews Immunology · doi:10.1038/nri1154 · Cited by 308
Ebola Virus VP40-Induced Particle Formation and Association with the Lipid Bilayer
Jasenosky, L. D., Neumann, G., Lukashevich, I., & Kawaoka, Y. (2001) · Journal of Virology · doi:10.1128/jvi.75.11.5205-5214.2001 · Cited by 286
Ebolavirus Glycoprotein Structure and Mechanism of Entry
Lee, J. E., & Saphire, E. O. (2009) · Future Virology · doi:10.2217/fvl.09.56 · Cited by 281
Antibodies to combat viral infections: development strategies and progress
Pantaleo, G., Correia, B., Fenwick, C., Joo, V. S., & Perez, L. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00495-3 · Cited by 279
Postexposure antibody prophylaxis protects nonhuman primates from filovirus disease
Dye, J. M., Herbert, A. S., Kuehne, A. I., Barth, J. F., Muhammad, M. A., Zak, S. E., Ortiz, R. A., Prugar, L. I., & Pratt, W. D. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1200409109 · Cited by 268
Passive immunotherapy of viral infections: 'super-antibodies' enter the fray
Walker, L. M., & Burton, D. R. (2018) · Nature Reviews Immunology · doi:10.1038/nri.2017.148 · Cited by 268
The antiviral activity of antibodies in vitro and in vivo
Parren, P. W. H. I., & Burton, D. R. (2001) · Advances in Immunology · doi:10.1016/s0065-2776(01)77018-6 · Cited by 261
Warfield, K. L., Swenson, D. L., Olinger, G. G., Kalina, W. V., Aman, M. J., & Bavari, S. (2007) · The Journal of Infectious Diseases · doi:10.1086/520583 · Cited by 260
Krenek, P., Samajova, O., Luptovciak, I., Doskocilova, A., Komis, G., & Samaj, J. (2015) · Biotechnology Advances · doi:10.1016/j.biotechadv.2015.03.012 · Cited by 258
Covalent Modifications of the Ebola Virus Glycoprotein
Jeffers, S. A., Sanders, D. A., & Sanchez, A. (2002) · Journal of Virology · doi:10.1128/jvi.76.24.12463-12472.2002 · Cited by 253
Saphire, E. O., Schendel, S. L., Fusco, M. L., Gangavarapu, K., Gunn, B. M., Wec, A. Z., Halfmann, P. J., Brannan, J. M., Herbert, A. S., Qiu, X., et al. (2018) · Cell · doi:10.1016/j.cell.2018.07.033 · Cited by 212
“Three independent assays for evaluation of mAb neutralization—Disparities in previous antibody-mediated neutralization results could be due to differing experimental conditions and model systems (Davidson et al., 2015; Li et al., 2016; Wilkinson et al., 2017; Wilson et al., 2000).”
InfluentialNonneutralizing Functional Antibodies: a New “Old” Paradigm for HIV Vaccines
Excler, J.-L., Ake, J., Robb, M. L., Kim, J. H., & Plotkin, S. A. (2014) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00230-14 · Cited by 114
Persistent infection with Ebola virus under conditions of partial immunity
Gupta, M., Mahanty, S., Greer, P., Towner, J. S., Shieh, W.-J., Zaki, S. R., Ahmed, R., & Rollin, P. E. (2004) · Journal of Virology · doi:10.1128/jvi.78.2.958-967.2004 · Cited by 85
Metadata
- Authors
- Wilson, J. A., Hevey, M., Bakken, R., Guest, S., Bray, M., Schmaljohn, A. L., & Hart, M. K.
- Venue
- Science
- Published
- 2000-03-03
- Volume
- 287
- Issue
- 5458
- Pages
- 1664-1666
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W1989676021
- Cited by
- 459
- References
- 11
- FWCI
- 14.24
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.